Medivation Inc (MDVN) 131.01 $MDVN
Medivation Announces First Quarter 2015 Financial Results Teleconference on May 7, 2015
Marketwired - Thu Apr 23, 3:10PM CDT
Medivation, Inc. (NASDAQ: MDVN) today announced that it will host a live teleconference with management to discuss first quarter 2015 financial results and provide a general business update on May 7, 2015 at 4:30 p.m. Eastern Time. A press release for the first quarter will be released after markets close on May 7, 2015.
MDVN: 131.01 (-1.50)
Downgrade Alert for Medivation (MDVN)
Comtex SmarTrend(R) - Mon Apr 20, 7:08AM CDT
Medivation (NASDAQ:MDVN) was downgraded from Outperform to Neutral at Credit Suisse today. The stock closed yesterday at $127.68 on volume of 814,000 shares, below average daily volume of 995,000. In the past 52 weeks, shares of Medivation have traded between a low of $54.37 and a high of $141.58 and closed yesterday at $127.68, which is 135% above that low price. The 200-day and 50-day moving averages have moved 1.31% higher and 2.16% higher over the past week, respectively.
MDVN: 131.01 (-1.50)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 4:36PM CDT
MNK: 122.01 (-2.84), FARO: 43.44 (-1.22), MDVN: 131.01 (-1.50), CRIS: 2.96 (-0.01), E: 36.82 (-0.26), PH: 122.49 (-0.94), YOKU: 17.03 (+0.12), FXCM: 2.08 (-0.03), VSLR: 14.50 (-0.20), IGT: 20.21 (+0.21)
Johnson & Johnson's Earnings: What You Need to Know
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Fri Apr 17, 9:01AM CDT
Healthcare giant Johnson & Johnson is one of the first multinationals to report earnings this quarter. While clearly instructive for current and potential J&J investors, the report also offers some insight into the broader sector and the...
MDVN: 131.01 (-1.50), JNJ: 101.08 (+0.62), PCYC: 256.59 (-0.51)
Health Canada Approves New Indication for the Use of Xtandi® (enzalutamide) Capsules for Patients with Metastatic Castration-Resistant Prostate Cancer
CNW Group - Thu Apr 16, 7:00AM CDT
Approval based on improved overall survival, delayed time to radiographic progression and an overall positive risk-benefit profile
MDVN: 131.01 (-1.50)
Tokai Pharmaceuticals Announces the Appointment of Cheryl Cohen, Former Medivation Chief Commercial Officer, to its Board of Directors
Business Wire - Mon Apr 13, 3:01PM CDT
Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, today announced the appointment of Cheryl Cohen, the former Chief Commercial Officer of Medivation, Inc., to its Board of Directors.
MDVN: 131.01 (-1.50), TKAI: 11.13 (-0.18)
Intersect ENT Appoints Kieran Gallahue and Tony Vernon to Board of Directors
Business Wire - Thu Apr 09, 6:35PM CDT
Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced the appointment of Kieran T. Gallahue and W. Anthony Vernon to the company's board of directors. Mr. Gallahue will serve as lead director and a member of the audit committee and Mr. Vernon will serve as chair of the nominating and corporate governance committee. Additionally, current director Casper de Clerq from Norwest Venture Partners has informed the board of directors that he will not seek re-election at the annual stockholder meeting in June.
MDVN: 131.01 (-1.50), XENT: 25.91 (-0.24), CFN: 59.91 (-0.06), VOLC: 17.99 (+0.01), ED: 62.50 (+0.40)
Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 2.82 (-0.05), NBS: 2.91 (-0.14), OSIR: 16.33 (-0.26), BCLI: 4.14 (+0.02), MDVN: 131.01 (-1.50), INO: 10.35 (-0.25), CYTX: 0.99 (+0.01), STEM: 0.61 (-0.21), JUNO: 56.66 (-1.06), ATHX: 1.29 (-0.03), CUR: 1.94 (-0.06), BLUE: 136.26 (-3.82), VRTX: 133.20 (-2.62), AMGN: 167.91 (-1.26), KERX: 11.41 (-0.32), OMER: 24.32 (-0.35), KITE: 60.58 (-0.35), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), TEVA: 64.41 (+1.16)
Medivation Looks Strong For 2015-2016
William Meyers - at Seeking Alpha - Thu Apr 09, 9:30AM CDT
MDVN: 131.01 (-1.50), JNJ: 101.08 (+0.62)
Medivation Rises 4.48% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Apr 08, 4:16PM CDT
Medivation (NASDAQ:MDVN) traded in a range yesterday that spanned from a low of $128.11 to a high of $134.16. Yesterday, the shares gained 4.5%, which took the trading range above the 3-day high of $131.96 on volume of 982,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MDVN: 131.01 (-1.50)
Astellas-Medivation's Xtandi Meets Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 06, 3:26PM CDT
Astellas Pharma Inc. (ALPMY) and Medivation announced positive top-line results from the phase II STRIVE study comparing Xtandi to Casodex in CRPC patients.
CYTK: 7.25 (-0.18), MDVN: 131.01 (-1.50), LCI: 67.40 (unch)
Xtandi beats Casodex in trial
at Investor's Business Daily - Thu Apr 02, 5:47PM CDT
The biotech Medivation (MDVN) reported another round of successful trial results for its prostate-cancer drug Xtandi. The drug outperformed bicalutamide, also known as AstraZeneca's (AZN) Casodex. The median progression-free survival for the group...
MDVN: 131.01 (-1.50), AZN: 71.79 (-1.34)
3 Stocks Driving The Health Care Sector Higher
at The Street - Thu Apr 02, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
MDVN: 131.01 (-1.50), SNN: 35.76 (+0.44), GRFS: 33.90 (+0.32)
Medivation's Xtandi Beats Casodex In Cancer Trial
at Investor's Business Daily - Thu Apr 02, 9:32AM CDT
Top-rated biotech Medivation (MDVN) reported another round of successful trial results for its prostate-cancer drug Xtandi Thursday, giving the stock a brief bump in early trading. Medivation and its partner Astellas said that a midstage trial...
MDVN: 131.01 (-1.50), MU: 29.20 (-0.31), JNJ: 101.08 (+0.62), AZN: 71.79 (-1.34), INTC: 32.08 (-0.27), SNDK: 67.92 (-0.84)
Xtandi successful in second Phase 2 prostate cancer study
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 7:56AM CDT
MDVN: 131.01 (-1.50)
Enzalutamide Demonstrates Statistically Significant Improvement in Progression Free Survival Compared With Bicalutamide in Strive Trial
Marketwired - Thu Apr 02, 6:00AM CDT
Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced topline results from the Phase 2 STRIVE trial comparing enzalutamide with bicalutamide in a study population of men with non-metastatic or metastatic castration-resistant prostate cancer. The study achieved its primary endpoint demonstrating a statistically significant increase in progression-free survival (PFS) for enzalutamide compared with bicalutamide (Hazard Ratio = 0.24; 95% Confidence Interval, 0.18-0.32; p < 0.0001). Median PFS was 19.4 months in the enzalutamide group compared with 5.7 months in the bicalutamide group.
MDVN: 131.01 (-1.50)
Enzalutamide Demonstrates Statistically Significant Improvement In Progression Free Survival Compared With Bicalutamide In Strive Trial
PR Newswire - Thu Apr 02, 6:00AM CDT
Astellas Pharma Inc. (TSE: 4503) and Medivation, Inc. (NASDAQ: MDVN) today announced topline results from the Phase 2 STRIVE trial comparing enzalutamide with bicalutamide in a study population of men with non-metastatic or metastatic castration-resistant prostate cancer. The study achieved its primary endpoint demonstrating a statistically significant increase in progression-free survival (PFS) for enzalutamide compared with bicalutamide (Hazard Ratio = 0.24; 95% Confidence Interval, 0.18-0.32; p<0.0001). Median PFS was 19.4 months in the enzalutamide group compared with 5.7 months in the bicalutamide group.
MDVN: 131.01 (-1.50)
Cancer PD-1 inhibitor market only half as large as consensus says analyst
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 11:37AM CDT
MDVN: 131.01 (-1.50), AZN: 71.79 (-1.34), MRK: 57.60 (+0.09), BMY: 65.80 (-0.20), SRNE: 10.52 (-0.15), CELG: 118.71 (+2.62), FPRX: 24.20 (-0.26)
Defensive Sectors Lead Hesitant Market, But Traders Honor Long-Standing Bullish Support
Scott Martindale - at Seeking Alpha - Tue Mar 31, 12:12AM CDT
Last week, the major indexes fell back below round-number thresholds that had taken a lot of effort to eclipse. There has been an ongoing ebb-and-flow of capital between risk-on and risk-off, including high sector correlations, which is far from...
VRX: 210.42 (+1.03), BMRN: 120.28 (-2.67), QABA: 36.83 (-0.23), OZRK: 39.42 (-0.43), MDVN: 131.01 (-1.50), IYZ: 31.57 (-0.14), SPY: 211.65 (+0.49), IDU: 113.60 (+1.08), IYW: 109.18 (+1.09), IYK: 106.81 (-0.31), IYJ: 108.52 (-0.55), IYH: 158.01 (-0.59), SWKS: 93.39 (-2.43), WAL: 31.03 (-0.35), FBT: 121.64 (-0.77), IYM: 84.56 (+0.48), IYC: 147.26 (+1.72), NXPI: 95.33 (-3.25), IYF: 89.54 (-0.17), IYE: 46.12 (-0.34), TSO: 89.63 (+3.13), IWM: 125.86 (-0.42), FONE: 41.73 (-0.20), FSL: 38.86 (-1.12), AVGO: 119.50 (-4.57), SLCA: 34.70 (-1.30)
Medivation Announces First Quarter 2015 Financial Results Teleconference on May 7, 2015
Marketwired - Thu Apr 23, 3:10PM CDT
Medivation, Inc. (NASDAQ: MDVN) today announced that it will host a live teleconference with management to discuss first quarter 2015 financial results and provide a general business update on May 7, 2015 at 4:30 p.m. Eastern Time. A press release for the first quarter will be released after markets close on May 7, 2015.
MDVN: 131.01 (-1.50)
Downgrade Alert for Medivation (MDVN)
Comtex SmarTrend(R) - Mon Apr 20, 7:08AM CDT
Medivation (NASDAQ:MDVN) was downgraded from Outperform to Neutral at Credit Suisse today. The stock closed yesterday at $127.68 on volume of 814,000 shares, below average daily volume of 995,000. In the past 52 weeks, shares of Medivation have traded between a low of $54.37 and a high of $141.58 and closed yesterday at $127.68, which is 135% above that low price. The 200-day and 50-day moving averages have moved 1.31% higher and 2.16% higher over the past week, respectively.
MDVN: 131.01 (-1.50)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 4:36PM CDT
MNK: 122.01 (-2.84), FARO: 43.44 (-1.22), MDVN: 131.01 (-1.50), CRIS: 2.96 (-0.01), E: 36.82 (-0.26), PH: 122.49 (-0.94), YOKU: 17.03 (+0.12), FXCM: 2.08 (-0.03), VSLR: 14.50 (-0.20), IGT: 20.21 (+0.21)
Johnson & Johnson's Earnings: What You Need to Know
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Fri Apr 17, 9:01AM CDT
Healthcare giant Johnson & Johnson is one of the first multinationals to report earnings this quarter. While clearly instructive for current and potential J&J investors, the report also offers some insight into the broader sector and the...
MDVN: 131.01 (-1.50), JNJ: 101.08 (+0.62), PCYC: 256.59 (-0.51)
Health Canada Approves New Indication for the Use of Xtandi® (enzalutamide) Capsules for Patients with Metastatic Castration-Resistant Prostate Cancer
CNW Group - Thu Apr 16, 7:00AM CDT
Approval based on improved overall survival, delayed time to radiographic progression and an overall positive risk-benefit profile
MDVN: 131.01 (-1.50)
Tokai Pharmaceuticals Announces the Appointment of Cheryl Cohen, Former Medivation Chief Commercial Officer, to its Board of Directors
Business Wire - Mon Apr 13, 3:01PM CDT
Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, today announced the appointment of Cheryl Cohen, the former Chief Commercial Officer of Medivation, Inc., to its Board of Directors.
MDVN: 131.01 (-1.50), TKAI: 11.13 (-0.18)
Intersect ENT Appoints Kieran Gallahue and Tony Vernon to Board of Directors
Business Wire - Thu Apr 09, 6:35PM CDT
Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced the appointment of Kieran T. Gallahue and W. Anthony Vernon to the company's board of directors. Mr. Gallahue will serve as lead director and a member of the audit committee and Mr. Vernon will serve as chair of the nominating and corporate governance committee. Additionally, current director Casper de Clerq from Norwest Venture Partners has informed the board of directors that he will not seek re-election at the annual stockholder meeting in June.
MDVN: 131.01 (-1.50), XENT: 25.91 (-0.24), CFN: 59.91 (-0.06), VOLC: 17.99 (+0.01), ED: 62.50 (+0.40)
Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 2.82 (-0.05), NBS: 2.91 (-0.14), OSIR: 16.33 (-0.26), BCLI: 4.14 (+0.02), MDVN: 131.01 (-1.50), INO: 10.35 (-0.25), CYTX: 0.99 (+0.01), STEM: 0.61 (-0.21), JUNO: 56.66 (-1.06), ATHX: 1.29 (-0.03), CUR: 1.94 (-0.06), BLUE: 136.26 (-3.82), VRTX: 133.20 (-2.62), AMGN: 167.91 (-1.26), KERX: 11.41 (-0.32), OMER: 24.32 (-0.35), KITE: 60.58 (-0.35), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), TEVA: 64.41 (+1.16)
Medivation Looks Strong For 2015-2016
William Meyers - at Seeking Alpha - Thu Apr 09, 9:30AM CDT
MDVN: 131.01 (-1.50), JNJ: 101.08 (+0.62)
Medivation Rises 4.48% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Apr 08, 4:16PM CDT
Medivation (NASDAQ:MDVN) traded in a range yesterday that spanned from a low of $128.11 to a high of $134.16. Yesterday, the shares gained 4.5%, which took the trading range above the 3-day high of $131.96 on volume of 982,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MDVN: 131.01 (-1.50)
Astellas-Medivation's Xtandi Meets Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 06, 3:26PM CDT
Astellas Pharma Inc. (ALPMY) and Medivation announced positive top-line results from the phase II STRIVE study comparing Xtandi to Casodex in CRPC patients.
CYTK: 7.25 (-0.18), MDVN: 131.01 (-1.50), LCI: 67.40 (unch)
Xtandi beats Casodex in trial
at Investor's Business Daily - Thu Apr 02, 5:47PM CDT
The biotech Medivation (MDVN) reported another round of successful trial results for its prostate-cancer drug Xtandi. The drug outperformed bicalutamide, also known as AstraZeneca's (AZN) Casodex. The median progression-free survival for the group...
MDVN: 131.01 (-1.50), AZN: 71.79 (-1.34)
3 Stocks Driving The Health Care Sector Higher
at The Street - Thu Apr 02, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
MDVN: 131.01 (-1.50), SNN: 35.76 (+0.44), GRFS: 33.90 (+0.32)
Medivation's Xtandi Beats Casodex In Cancer Trial
at Investor's Business Daily - Thu Apr 02, 9:32AM CDT
Top-rated biotech Medivation (MDVN) reported another round of successful trial results for its prostate-cancer drug Xtandi Thursday, giving the stock a brief bump in early trading. Medivation and its partner Astellas said that a midstage trial...
MDVN: 131.01 (-1.50), MU: 29.20 (-0.31), JNJ: 101.08 (+0.62), AZN: 71.79 (-1.34), INTC: 32.08 (-0.27), SNDK: 67.92 (-0.84)
Xtandi successful in second Phase 2 prostate cancer study
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 7:56AM CDT
MDVN: 131.01 (-1.50)
Enzalutamide Demonstrates Statistically Significant Improvement in Progression Free Survival Compared With Bicalutamide in Strive Trial
Marketwired - Thu Apr 02, 6:00AM CDT
Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced topline results from the Phase 2 STRIVE trial comparing enzalutamide with bicalutamide in a study population of men with non-metastatic or metastatic castration-resistant prostate cancer. The study achieved its primary endpoint demonstrating a statistically significant increase in progression-free survival (PFS) for enzalutamide compared with bicalutamide (Hazard Ratio = 0.24; 95% Confidence Interval, 0.18-0.32; p < 0.0001). Median PFS was 19.4 months in the enzalutamide group compared with 5.7 months in the bicalutamide group.
MDVN: 131.01 (-1.50)
Enzalutamide Demonstrates Statistically Significant Improvement In Progression Free Survival Compared With Bicalutamide In Strive Trial
PR Newswire - Thu Apr 02, 6:00AM CDT
Astellas Pharma Inc. (TSE: 4503) and Medivation, Inc. (NASDAQ: MDVN) today announced topline results from the Phase 2 STRIVE trial comparing enzalutamide with bicalutamide in a study population of men with non-metastatic or metastatic castration-resistant prostate cancer. The study achieved its primary endpoint demonstrating a statistically significant increase in progression-free survival (PFS) for enzalutamide compared with bicalutamide (Hazard Ratio = 0.24; 95% Confidence Interval, 0.18-0.32; p<0.0001). Median PFS was 19.4 months in the enzalutamide group compared with 5.7 months in the bicalutamide group.
MDVN: 131.01 (-1.50)
Cancer PD-1 inhibitor market only half as large as consensus says analyst
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 11:37AM CDT
MDVN: 131.01 (-1.50), AZN: 71.79 (-1.34), MRK: 57.60 (+0.09), BMY: 65.80 (-0.20), SRNE: 10.52 (-0.15), CELG: 118.71 (+2.62), FPRX: 24.20 (-0.26)
Defensive Sectors Lead Hesitant Market, But Traders Honor Long-Standing Bullish Support
Scott Martindale - at Seeking Alpha - Tue Mar 31, 12:12AM CDT
Last week, the major indexes fell back below round-number thresholds that had taken a lot of effort to eclipse. There has been an ongoing ebb-and-flow of capital between risk-on and risk-off, including high sector correlations, which is far from...
VRX: 210.42 (+1.03), BMRN: 120.28 (-2.67), QABA: 36.83 (-0.23), OZRK: 39.42 (-0.43), MDVN: 131.01 (-1.50), IYZ: 31.57 (-0.14), SPY: 211.65 (+0.49), IDU: 113.60 (+1.08), IYW: 109.18 (+1.09), IYK: 106.81 (-0.31), IYJ: 108.52 (-0.55), IYH: 158.01 (-0.59), SWKS: 93.39 (-2.43), WAL: 31.03 (-0.35), FBT: 121.64 (-0.77), IYM: 84.56 (+0.48), IYC: 147.26 (+1.72), NXPI: 95.33 (-3.25), IYF: 89.54 (-0.17), IYE: 46.12 (-0.34), TSO: 89.63 (+3.13), IWM: 125.86 (-0.42), FONE: 41.73 (-0.20), FSL: 38.86 (-1.12), AVGO: 119.50 (-4.57), SLCA: 34.70 (-1.30)
